Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade
Tumor associated neutrophils have been correlated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here the authors show that the tyrosine kinase inhibitor lorlatinib modulates neutrophil development and recruitment in the tumor microenvironment, attenuating PDAC progres...
Saved in:
Main Authors: | Sebastian R. Nielsen, Jan E. Strøbech, Edward R. Horton, Rene Jackstadt, Anu Laitala, Marina C. Bravo, Giorgia Maltese, Adina R. D. Jensen, Raphael Reuten, Maria Rafaeva, Saadia A. Karim, Chang-Il Hwang, Luis Arnes, David A. Tuveson, Owen J. Sansom, Jennifer P. Morton, Janine T. Erler |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/80c3347050694832b4503df3a10d5b8d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by: Hayato Mizuta, et al.
Published: (2021) -
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015) -
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
by: Haoxin Li, et al.
Published: (2019) -
Predictors of responses to immune checkpoint blockade in advanced melanoma
by: N. Jacquelot, et al.
Published: (2017) -
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
by: Xiaopin Duan, et al.
Published: (2019)